-
Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
China Net Finance, November 7th (Reporter Chen Qiong) On November 6th, Novo Nordisk held the launch ceremony of "Healthy China Action - Metabolic Renewal Year" at the Novo Nordisk booth at the 7th Ch ... -
Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals regarding the patent dispute over the weight loss drugs Ozempic and Wegovy. Novo Nordisk and Mylan Pharmaceuticals, a subsidiary of Vi ... -
Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
On October 5th, according to Southern Finance, Danish pharmaceutical company Novo Nordisk announced on Friday that it will invest 864 million Brazilian reals ($158.2 million) to renovate a factory in ...- liujingwen
- 2024-10-5 10:59
- 支持
- 反对
- 回复
- 收藏
-
Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
Danish pharmaceutical company Novo Nordisk announced on Friday that it will invest 864 million Brazilian reals ($158.2 million) to renovate a factory in Brazil that produces a quarter of Novo Nordisk ... -
The US Senate questions whether the pricing of the "weight loss miracle drug" is too high. Nuo and Nuo De respond that lowering the price is useless
[The US Senate questioned that the "weight-loss wonder drug" was overpriced. Novo and Nordisk responded that it was useless to cut the price.] On Tuesday (September 24), the CEO of Danish pharmaceuti ... -
Novo Nordisk faces US Senate inquiry over weight loss drug prices
According to the website of the United States Senate, the Senate will hold a hearing on September 24 local time to examine whether Novo Nordisk provides overpriced smeglutide products Ozempic and Weg ... -
Is the dual monopoly situation of Novo Nordisk Lilly in danger? By 2029, there may be 16 GLP-1 weight loss drugs on the market
According to analysts from Morningstar and Pitchbook, it is estimated that there will be 16 new GLP-1 drugs launched in the weight loss drug market by 2029, competing for the lucrative market current ... -
Oral "weight loss medication" further advances Novo Nordisk oral semaglutide weight loss phase III research success
Reporter Chen Xing On August 7th, Novo Nordisk announced its H1 2024 results that the Phase III OASIS 4 study on weight loss with oral semaglutide Rybelsus (25mg) has been successfully completed. Ora ... -
Holding the 'miracle drug for weight loss', Novo Nordisk generates 133.4 billion DKK in revenue in H1 2024
On August 7, 2024, Novo Nordisk released its financial report for the first half of 2024, with operating revenue of 133.4 billion Danish kroner (DKK), equivalent to 19.5 billion US dollars, a year-on ... -
Novo Nordisk's US stock fell more than 5% before trading
On August 7th, Novo Nordisk's US stock market fell more than 5% in pre-market trading, after lowering its profit expectations. -
"Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
On June 27th, it was reported in the market that the "weight loss miracle drug" Wegovy (Chinese product name: Nuoheying) will be sold in limited quantities in China. On June 28th, relevant personnel ... -
Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
21st Century Business Herald reporter Ji Yuanyuan reports from Shanghai Recently, the first injectable version of Smegglutide for long-term weight management, Novoying&Co., Ltd; reg; Finally, it was ... -
Novo Nordisk responds that semaglutide may cause male impotence
On June 4th, Novo Nordisk China told reporters that according to approved US prescription information or EU product feature summaries, sexual dysfunction is not a side effect mentioned in the Wegovy ... -
The GLP-1 theme fund in the US stock market triggers thinking. Who will be the next "Novo Nordisk"?
With a thematic investment fund betting on the long-term explosive potential of the GLP-1 track sparking discussions, the US stock market is also starting to examine which pharmaceutical companies be ... -
What is the research and development direction of weight loss drugs for Novo Nordisk after the entry of multiple giants
On May 21, the GIP/GLP-1 receptor dual agonist tirzepatide of Eli Lilly was approved by the National Drug Administration (NMPA) of China to treat adult type 2 diabetes patients for blood glucose cont ... -
Is Novo Nord Wegovy really that divine? New research will test whether it can treat alcoholic liver disease
Novo Nordisk is conducting a new round of trials on its weight-loss medication to explore whether using it can help people reduce their alcohol intake and treat alcoholic liver disease. At present, t ... -
Novo Nordisk's "miracle weight loss medicine" new research: Not losing weight can also reduce the risk of heart disease
As early as November last year, Danish pharmaceutical giant Novo Nordisk officially claimed that its globally popular weight loss drug Wegovy (chemical name Smegglutide) can reduce the risk of cardio ... -
Earning too much! US Senators indirectly pressure Novo Nordisk to lower the price of weight loss pills
On Monday local time, US Senator Bernie Sanders wrote a letter to Politburo, one of the largest newspapers in Nordic countries, urging Denmark to pressure the well-known pharmaceutical company Novo N ... -
Novo Nordisk promises to invest $6 billion to expand production capacity. Prices of weight loss drugs in the United States are expected to further decrease
On Thursday, weight loss drug giant Novo Nordisk held a earnings conference call, promising to further adopt a price reduction strategy in the US market. The company's Chief Financial Officer, Karste ... -
The founding family of Nordstrom is reportedly seeking to privatize the company
On March 20th, it was reported that the founding family of Nordstrom is seeking to privatize this American department store. Sources say Nordstrom has requested Morgan Stanley and Centerview Partners ...